Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | MERTK | Q12866 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11908199 | 0.80 | RPS6KA3 (0.43) | SLC22A12ALDH1A1TDP1HTTRAB9A | |
| SCHEMBL28763125 | 0.80 | RPS6KA3 (0.58) | SLC22A12ALDH1A1TDP1HTTRAB9A | |
| SCHEMBL29939436 | 0.80 | ALDH1A1 (0.57) | SLC22A12ALDH1A1TDP1HTTRAB9A | |
| SCHEMBL3591834 | 0.80 | ALDH1A1 (0.57) | SLC22A12ALDH1A1TDP1HTTRAB9A | |
| SCHEMBL3171796 | 0.80 | MEN1 (0.45) | SLC22A12ALDH1A1TDP1HTTRAB9A | |
| SCHEMBL4952534 | 0.80 | AHR (0.42) | SLC22A12ALDH1A1TDP1HTTRAB9A | |
| SCHEMBL29973546 | 0.79 | ALDH1A1 (0.61) | CYP11B2CYP11B1ALDH1A1TDP1HTT | |
| SCHEMBL20189898 | 0.79 | ALDH1A1 (0.61) | CYP11B2CYP11B1ALDH1A1TDP1HTT | |
| SCHEMBL6981433 | 0.78 | ALDH1A1 (0.65) | VCAM1ALDH1A1MERTKTDP1 | |
| SCHEMBL27806615 | 0.76 | VCAM1 (0.58) | VCAM1ALDH1A1MERTKTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110225912-B | GSK-3 inhibitors | 百时美施贵宝公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-3544980-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10774086-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774086-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3544980-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276463-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018098411-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276463-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | SLC22A12 3915/4885CYP11B2 265/4885VCAM1 4022/4885 |
| US-10774086-B2 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | SLC22A12 3915/4885CYP11B2 265/4885VCAM1 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.